Next Article in Journal
Assessment of Nonnucleoside Inhibitors Binding to HIV-1 Reverse Transcriptase Using HYDE Scoring
Next Article in Special Issue
Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
Previous Article in Journal / Special Issue
Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
Open AccessBrief Report

Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines

by 1,2 and 1,2,*
1
Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
2
CIIMAR, Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos P, 4450-208 Matosinhos, Portugal
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(2), 63; https://doi.org/10.3390/ph12020063
Received: 10 March 2019 / Revised: 16 April 2019 / Accepted: 18 April 2019 / Published: 21 April 2019
(This article belongs to the Collection The Story of Successful Drugs and Recent FDA-Approved Molecules)
Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek Pharmaceuticals. It is a semisynthetic compound, derived from minocycline, capable of evading widely distributed efflux and target protection antibacterial resistance mechanisms and has demonstrated activity in a broad spectrum of bacteria. View Full-Text
Keywords: Omadacycline; aminomethylcycline; tetracycline; antibacterial; protein synthesis inhibitor; FDA approved Omadacycline; aminomethylcycline; tetracycline; antibacterial; protein synthesis inhibitor; FDA approved
Show Figures

Figure 1

MDPI and ACS Style

Durães, F.; Sousa, E. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals 2019, 12, 63. https://doi.org/10.3390/ph12020063

AMA Style

Durães F, Sousa E. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals. 2019; 12(2):63. https://doi.org/10.3390/ph12020063

Chicago/Turabian Style

Durães, Fernando; Sousa, Emília. 2019. "Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines" Pharmaceuticals 12, no. 2: 63. https://doi.org/10.3390/ph12020063

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop